natgillin/translations-raw huggingface dataset:
The receiver of claim 12, wherein the L1 block has L1 signaling information for the data slice. 
Uređaj prema zahtjevu 11 ili 12, naznačen time, što L1 blok ima L1 signalizacijsku informaciju za signaliziranje podatkovnog odsječka.
The unit according to any of the previous claims, wherein the working surfaces of said splicing cylinders (11, 12) are slightly corrugated, so that longitudinal ridges are generated in order to reduce the contact surface area when the cylinders come into contact with each other. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da su radne površine navedenih valjaka za spajanje (11, 12) blago nabrane tako da se stvaraju uzdužne brazde kako bi se smanjila kontaktna površina kada valjci međusobno dođu u kontakt.
represents C1-2-alkyl; A represents wherein the asterisks indicate the bond that is linked to the Pyridine1 ring; 
predstavlja C1-2-alkil; A predstavlja [image] [image] ili [image], gdje zvjezdice označavaju vezu koja je spojena na prsten Piridin1;
or a salt of such a compound. 
ili sol takvog spoja.
represents C1-2-alkyl; represents methyl; 
predstavlja C1-2-alkil; predstavlja metil;
A pharmaceutical composition comprising a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da sadrži spoj prema bilo kojem zahtjevu 1 do 13, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljiv nosač.
Use of a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the prevention or treatment of diseases or disorders associated with an activated immune system. 
Uporaba spoja prema bilo kojem zahtjevu 1 do 13, ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju farmaceutskog sastava za prevenciju ili liječenje bolesti ili poremećaja povezanih sa aktiviranjem imuno-sustava.
represents alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, haloalkyl, hydroxyalkyl, heterocycloalkenyl, alkylaryl, arylalkyl, alkylalkoxycarbonyl, alkylcarbonyloxy, or alkoxyalkyl, all of which are optionally substituted by one or more, same or different substituents selected from R5; or R2 represents hydrogen or -CH2-C(O)NR9-R12; 
predstavlja alkil, cikloalkil, alkenil, cikloalkenil, alkinil, haloalkil, hidroksialkil, heterocikloalkenil, alkilaril, arilalkil, alkilalkoksikarbonil, alkilkarboniloksi, ili alkoksialkil, gdje su svi oni izborno supsitituirani sa jednim ili više, istih ili različitih supstituenata izabranih od R5; ili R2 predstavlja vodik ili -CH2-C(O)NR9-R12;
or R7 represents hydrogen, halogen, or oxo; 
ili R7 predstavlja vodik, halogen, ili okso;
with the proviso that when R1 is methyl or hydrogen, R2 is methyl and R3 is hydrogen, then ring B cannot be phenyl; 
uz uvjet da kada je R1 jednak metil ili vodik, R2 je metil i R3 je vodik, tada prsten B ne može biti fenil;
A compound according to any one of the preceding claims wherein R3 represents methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxyethyl, butenyl, pentenyl, allyl, butinyl, benzyl, methylbenzene, ethylbenzene, ethylpyridine, tolyl, toluoyl, propylbenzene, methylnaphthyl, ethylnaphthyl, methylcarbonylmethoxy, methylcarbonylethoxy, methoxyethyl, methoxypropyl, all of which are optionally substituted by one or more, same or different substituents selected from R6, said R6 substituent being optionally substituted with one or more, same or different substituents selected from R8, or R3 represents hydrogen, -CH2-C(O)-heterocycloalkyl or -CH2-C(O)NR9-R12. 
Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što R3 predstavlja metil, etil, propil, butil, pentil, heksil, hidroksietil, butenil, pentenil, alil, butinil, benzil, metilbenzen, etilbenzen, etilpiridin, tolil, toluoil, propilbenzen, metilnaftil, etilnaftil, metilkarbonilmetoksi, metilkarboniletoksi, metoksietil, metoksipropil, gdje su svi oni izborno supsitituirani sa jednim ili više, istih ili različitih supstituenata izabranih od R6, pri čemu je navedeni R6 supstituent izborno supstituiran sa jednim ili više, istih ili različitih supstituenata izabranih od R8, ili R3 predstavlja vodik, -CH2-C(O)-heterocikloalkil ili -CH2-C(O)NR9-R12.
A compound according to any one of the preceding claims wherein R8 represents, methyl, ethyl, propyl, butyl, phenyl, cyclopropyl, ethoxy, methoxy, allyl, ethenyl, ethoxycarbonyl, hydroxy, naphthyl, cyclohexyl, methoxycarbonyl, phenxoxy, isopropoxy, -NH2, methylamine, pyrrolidinyl, morpholinyl, methylsulfonyl, methylsulfinyl, cycloheptyl, cyclopentyl, hydroxymethyl, hydroxyethyl, dimethylamino, furanyl, pyridyl, tolyl, piperidinyl, acetyl, thiophenyl, cycloheptyl, all of which are optionally substituted by one or more, same or different substituents selected from R10, or R8 represents hydrogen, oxo, chloro, bromo, fluoro, cyano, or trifluoromethyl. 
Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što R8 predstavlja, metil, etil, propil, butil, fenil, ciklopropil, etoksi, metoksi, alil, etenil, etoksikarbonil, hidroksi, naftil, cikloheksil, metoksikarbonil, fenoksi, izopropoksi, -NH2, metilamin, pirolidinil, morfolinil, metilsulfonil, metilsulfinil, cikloheptil, ciklopentil, hidroksimetil, hidroksietil, dimetilamino, furanil, piridil, tolil, piperidinil, acetil, tiofenil, cikloheptil, gdje su svi oni izborno supsitituirani sa jednim ili više, istih ili različitih supstituenata izabranih od R10, ili R8 predstavlja vodik, okso, kloro, bromo, fluoro, cijano ili trifluorometil.
A compound according to claim 1 selected from 
Spoj prema patentnom zahtjevu 1, naznačen time, što je izabran od slijedećih
The use of a compound according to formula I wherein X1, X2, X3, X4 and X5 independently of each other represent -CH- or N; 
Primjena spoja prema formuli I [image] naznačena time što X1, X2, X3, X4 i X5 međusobno nezavisno predstavljaju -CH- ili N;
and pharmaceutically acceptable salts, hydrates, N-oxides or solvates thereof in the manufacture of a medicament for the prophylaxis, treatment or amelioration of dermal diseases or conditions, or acute or chronic cutaneous wound disorders. 
i njegovih farmaceutski prihvatljivih soli, hidrata, N-oksida ili solvata u proizvodnji lijeka za prevenciju, liječenje ili poboljšanje kožnih bolesti ili stanja, ili akutnih ili kroničnih rana na koži.
Natural mineral water according to claim 1 for use in the prophylaxis and treatment of paradontopathy. 
Prirodna mineralna voda prema zahtjevu 1 naznačena time da je za upotrebu kod profilakse i tretmana paradontopatije.
Natural mineral water according to claim 1 for use in the prophylaxis and treatment of dental caries. 
Prirodna mineralna voda prema zahtjevu 1 naznačena time da je za upotrebu kod profilakse i tretmana zubnog karijesa.
A process for the asymmetric alkylation of a carbonyl group in a compound (compound K) containing a carbonyl group and an anchor group selected from the group consisting of hydroxyl, amino and sulfhydryl groups, comprising the steps of: 
Postupak za asimetričnu alkilaciju karbonilne skupine u spoju (spoj K) koji sadrži karbonilnu skupinu i pričvrsnu skupinu odabrane iz skupine koja sadrži hidroksil, amino i sulfhidril skupine, naznačen time, da obuhvaća sljedeće korake:
adding an organometallic compound which is an organomagnesium compound. 
dodavanje organometalnog spoja koji je spoj organomagnezija.
The process of claim 1 or 2, wherein the reaction mixture is subjected to substantial removal of the side products of step a) before step b). 
Postupak prema zahtjevu 1 ili 2, naznačen time, da se reakcijska smjesa izlaže bitnom odstranjivanju sporednih proizvoda u koraku a) prije koraka b).
The process of claim 5 in combination with claim 3, wherein the reaction mixture is subjected to a distillation before step b) to remove water or a C1-10-alkanol. 
Postupak prema zahtjevu 5 u kombinaciji sa zahtjevom 3, naznačen time, da se reakcijska smjesa izlaže destilaciji prije koraka b) zbog odstranjivanja vode ili C1-10-alkanola.
The process of claim 9, wherein the carbon atom of the carbonyl group is separated from the carbon atom carrying the anchor group by 1,3 to 3 Angstrom. 
Postupak prema zahtjevu 9, naznačen time, da je atom ugljika iz ugljične skupine odvojen od atoma ugljika koji nosi uporišnu skupinu sa 1,3 do 3 Angstroma.
The process of claim 18, wherein a phenyl substituent is placed adjacent to the keto group in compound K. 
Postupak prema zahtjevu 18, naznačen time, da u spoju K je fenilni supstituent smješten susjedno uz keto skupinu.;20.
The process of any one of claims 1 to 19, wherein compound K is a compound of formula (III) wherein Y is cyano or a group which is convertible to a cyano group, wherein the group which is convertible to a cyano group is halogen, CF3-(CF2)n-SO2-O-, wherein n is 0 to 8; CH2OH or protected CH2OH, CH2NH2 or a protected -CH2NH2, -CH2NO2, -CH2Cl, -CH2Br, -CH3, -NHR2, -CHNOH, -COOR3, -OR2, wherein R2 is hydrogen or C1-6 alkylcarbonyl; CONR3R4 wherein R3 and R4 are selected from hydrogen, optionally substituted C1-6 alkyl, aryl-C1-6 alkyl or aryl, or R3 and R4 are linked together to form a 5- or 6-membered ring optionally comprising a S, O, or additional N atom; or CHOR5OR6 wherein R5 and R6 are independently selected from alkyl, aryl, heteroaryl, or R5 and R6 are linked together to form a 5- or 6-membered ring; or other protected -CHO groups, optionally substituted oxazole, 4,5-dihydrooxazole, thiazole, or 4,5-dihydrothiazole. 
Postupak prema bilo kojem zahtjevu 1 do 19, naznačen time, da spoju K je spoj formule (III) [image] gdje Y je cijano ili skupina koja se pretvara u cijano skupinu, dok skupina koja se pretvara u cijano skupinu je halogen, CF3-(CF2)n-SO2-O-, dok n je 0 do 8; CH2OH ili zaštićen CH2OH,CH2NH2ili zaštićen -CH2NH2, -CH2NO2, -CH2Cl, -CH2Br, -CH3, -NHR2, -CHNOH, -COOR3, -OR2, gdje R2 je vodik ili C1-6 alkilkarbonil; CONR3R4gdje R3 i R4 su odabrani od vodika, opcijski supstituiranih C1-6 alkila, aril-C1-6 alkila ili arila, ili R3 i R4 su spojeni zajedno za tvorbu 5-ili 6-članog prstena koji opcijski obuhvaća S, O, ili dodatno N atom; ili CHOR5OR6 gdje R5 i R6 su neovisno odabrani od alkila, arila, heteroarila, ili R5 i R6 su spojeni zajedno za tvorbu 5- ili 6-članog prstena; ili ostale zaštićene -CHO skupine, opcijski supstituirani oksazol, 4,5-dihidrooksazol, tiazol, ili 4,5-dihidrotiazol.;21.
The process of claim 21, wherein M is Mg and wherein Z is -CH2-N(CH3)2 or a group that may be converted to -CH2-N(CH3)2, wherein a diol of formula (II) is obtained in enantiomerically enriched or enantiomerically pure form wherein Y is cyano or a group which is convertible to a cyano group as defined in claim 20. 
Postupak prema zahtjevu 21, naznačen time, da M je Mg i gdje Z je -CH2-N(CH3)2 ili skupina koja se može pretvoriti u -CH2-N(CH3)2, pri čemu je dobiven diol formule (II) u obogaćenom enantiomernom ili čistom enantiomernom obliku, [image] dok Y je cijano skupina ili je skupina koja se pretvara u cijano skupinu kao što je određeno u zahtjevu 20.;23.
A compound of formula (V) wherein R1 is C1-10-alkyl or C1-10-alkoxy; wherein Y is cyano or a group which is convertible to a cyano group; and wherein O-R* is the residue of a chiral alcohol, wherein the group which is convertible to a cyano group is halogen, CF3-(CF2)n-SO2-O-wherein n is 0 to 8, CH2OH or protected CH2OH, CH2NH2 or a protected -CH2NH2, -CH2NO2, -CH2Cl, -CH2Br, -CH3, -NHR2, -CHNOH, -COOR3, -OR2, wherein R2 is hydrogen or C1-6 alkylcarbonyl; CONR3R4 wherein R3 and R4 are selected from hydrogen, optionally substituted C1-6 alkyl, aryl-C1-6 alkyl or aryl, or R3 and R4 are linked together to form a 5- or 6-membered ring optionally comprising a S, O, or additional N atom; or CHOR5OR6 wherein R5 and R6 are independently selected from alkyl, aryl, heteroaryl, or R5 and R6 are linked together to form a 5- or 6-membered ring; or other protected -CHO groups, optionally substituted oxazole, 4,5-dihydrooxazole, thiazole, or 4,5-dihydrothiazole. 
Spoj formule (V) [image] naznačen time, da R1 je C1-10-alkil ili C1-10-alkoksi; dok Y je cijano skupina ili skupina koja se pretvara u cijano skupinu; i pri čemu O-R* je talog kiralnog alkohola, gdje skupina koja se pretvara u cijano skupinu je halogen, CF3-(CF2)n-SO2-O-gdje n je 0 do 8, CH2OH ili zaštićen CH2OH, CH2NH2 ili zaštićeni -CH2NH2, -CH2NO2, -CH2Cl, -CH2Br, -CH3, -NHR2, -CHNOH, -COOR3, -OR2, pri čemu R2 je vodik ili C1-6 alkilkarbonil; CONR3R4 gdje R3 i R4su odabrani od vodika, opcijski supstituiranih C1-6 alkila, aril-C1-6 alkila ili arila, ili R3 i R4 su spojeni zajedno za tvorbu 5- ili 6-članog prstena koji opcijski obuhvaća S, O, ili dodatno N atom; ili CHOR5OR6, dok R5 i R6 su neovisno odabrani od alkila, arila, heteroarila, ili R5 i R6 su spojeni zajedno za tvorbu 5- ili 6-članog prstena; ili ostale zaštićene -CHO skupine, opcijski supstituirani oksazol, 4,5-dihidrooksazol, tiazol, ili 4,5-dihidrotiazol.
A holder to dispense ice coffee, consisting of a first compartment with a pressure medium, a second compartment with a liquid coffee extract composition and whereby both compartments are separated from each other, a nozzle and a valve and characterised by the fact that the composition consists of a liquid coffee concentrate and at least one additive, such as sugar, an artificial sweetener and an aroma or a combination thereof. 
Nosač za točenje ledene kave koji se sastoji od prve komore s tlačnim medijem, druge komore s tekućom smjesom ekstrakta kave, pri čemu su obje komore međusobno razdvojene, te mlaznice i ventila, naznačen time, da se smjesa sastoji od tekućeg koncentrata kave i barem jednog dodatka, poput šećera, umjetnog sladila i arome ili njihove kombinacije.
A holder to dispense ice coffee according to claim 1 and characterised by the fact that the composition proportionally consists of 80-90% coffee concentrate, 0-2% artificial sweeteners, 0-20% mono-and disaccharides, 0-10% aromatic additives and 0.1-2% propellant. 
Nosač za točenje ledene kave prema zahtjevu 1, naznačen time, da se smjesa proporcionalno sastoji od 80-90% koncentrata kave, 0-2% umjetnih sladila, 0-20% mono i disaharida, 0-10% aromatskih dodataka i 0,1-2% propelanta.
A holder to dispense ice coffee according to claims 1-3 and characterised by the fact that the sugars belong to the group of dextrose, fructose, glucose, saccharose (sucrose) and maltose. 
Nosač za točenje ledene kave prema zahtjevima 1 do 3, naznačen time, da su šećeri iz skupina dekstroza, fruktoza, glukoza, saharoza (sukroza) i maltoza.
A holder to dispense ice coffee according to claims 1-4 and characterised by the fact that the artificial sweeteners belong to the group of acesulfame K, sucralose, saccharine, aspartame, mannitol, sorbitol and xylitol. 
Nosač za točenje ledene kave prema zahtjevima 1 do 4, naznačen time, da su umjetna sladila iz skupina acesulfam K, sukraloza, saharin, aspartame, manitol, sorbitol i ksilitol.
A holder to dispense ice coffee according to claims 1-2 and characterised by the fact that the aromatic additives, both natural and artificial, belong to the group of vanilla, nuts, alcohol-free flavouring and milk aroma. 
Nosač za točenje ledene kave prema zahtjevima 1 do 2, naznačen time, da su aromatski dodaci, kako prirodni tako i umjetni, iz skupina vanilija, orašasti plodovi, bezalkoholne arome i arome mlijeka.
A holder to dispense ice coffee according to claims 1-6 and characterised by the fact that the additives can be added to the liquid coffee extract in a liquid, solid, viscous or gel-like state. 
Nosač za točenje ledene kave prema zahtjevima 1 do 6, naznačen time, da se dodaci mogu dodavati tekućem ekstraktu kave u tekućem, krutom, žitkom ili želatinoznom stanju.
A holder to dispense ice coffee according to one of the above-mentioned claims and characterised by the fact that the liquid coffee extract composition is sprayed as a jet onto a liquid, such as milk. 
Nosač za točenje ledene kave prema jednom od prethodnih zahtjeva, naznačen time, da se tekuća smjesa ekstrakta kave prska u obliku mlaza na tekućinu, kao što je mlijeko.
A holder to dispense ice coffee according to claims 1-8 and characterised by the fact that the contents are dispensed by facing the nozzle downwards. 
Nosač za točenje ledene kave prema zahtjevima 1 do 8, naznačen time, da se sadržaj izručuje mlaznicom usmjerenom prema dolje.
A dispensing device to prepare ice coffee according to claims 1-10 with at least one holder, fitted with a first compartment containing a pressure medium, a second compartment containing a liquid coffee extract with at least one additive, and whereby the two compartments are separated from each other, and a nozzle to dispense ice coffee and characterised by the fact that the holder is fitted in such a manner that the contents can be sprayed onto a liquid by means of the pressure medium, to prepare ice coffee. 
Dozirni uređaj za pripremu ledene kave prema zahtjevima 1 do 10, koji obuhvaća barem jedan nosač, učvršćen na prvu komoru koja sadrži tlačni medij, zatim s drugom komorom koja sadrži tekući ekstrakt kave s barem jednim dodatkom, pri čemu su dvije komore međusobno razdvojene, te s mlaznicom za izručivanje ledene kave, naznačen time, da je nosač postavljen na takav način da se sadržaj može prskati na tekućinu pomoću tlačnog medija, za pripremu ledene kave.
A dispensing device to prepare ice coffee according to claim 11 and characterised by the fact that the dispensing device allows the consumer to make a choice of various holders with liquid coffee extracts, containing other additives and compositions. 
Dozirni uređaj za pripremu ledene kave prema zahtjevu 11, naznačen time, da dozirni uređaj omogućava korisniku biranje različitih nosača s tekućim ekstraktima kave, koji sadrže različite dodatke i smjese.
A dispensing device to prepare ice coffee according to claims 11-12 and characterised by the fact that ground ice shavings can be added. 
Dozirni uređaj za pripremu ledene kave prema zahtjevima 11 do 12, naznačen time, da se mogu dodavati mljevene strugotine leda.
A dispensing device to prepare ice coffee according to claims 11-13 and characterised by the fact that the a refrigerating device can be installed. 
Dozirni uređaj za pripremu ledene kave prema zahtjevima 11 do 13, naznačen time, da se može ugraditi uređaj za hlađenje.
is hydrogen or up to three substituents independently selected from halogen, C(1-4)alkyl, C(1-4)alkoxy, trifluoromethoxy, difluoromethoxy, trifluoromethyl, cyano, and optionally substituted phenyl or optionally substituted 5 or 6 membered heteroaryl rings; 
je vodik ili do tri supstituenta, koje se neovisno bira između halogena, C(1-4)alkila, C(1-4)alkoksi, trifluormetoksi, difluormetoksi, trifluormetila, cijano i izborno supstituiranih fenilnih ili izborno supstituiranih 5- ili 6-eročlanih heteroarilnih prstena;
is hydrogen or up to three substituents independently selected from halogen, C(1-4)alkyl, C(1-4)alkoxy, trifluoromethoxy, difluoromethoxy, trifluoromethyl and cyano; 
je vodik ili do tri supstituenta, koje se neovisno bira između halogena, C(1-4)alkila, C(1-4)alkoksi, trifluormetoksi, difluormetoksi, trifluormetila i cijano;
X is a direct bond; 
X je izravna veza;
n is 0-4; and when R1 comprises a substituted phenyl or 5 or 6 membered heteroaryl ring, it is substituted by up to three substituents independently selected from halogen, C(1-4)alkyl, C(1-4)alkoxy, trifluoromethoxy, difluoromethoxy, trifluoromethyl and cyano. 
n je 0-4; i kada R1 je supstituirani fenil ili 5- ili 6-eročlani heteroarilni prsten, isti je supstituiran s do tri supstituenta, koje se neovisno bira između halogena, C(1-4)alkila, C(1-4)alkoksi, trifluormetoksi, difluormetoksi, trifluormetila i cijano.
The apparatus of claim 11 or 12, wherein the L1 block has L1 signaling information for signaling the data slice. 
Uređaj prema zahtjevu 11 ili 12, naznačen time, što L1 blok ima L1 signalizacijsku informaciju za signaliziranje podatkovnog odsječka.
A method according to claim 1, wherein component A) is a compound of formula I, wherein R1 is difluoromethyl, Y is ―CHR2- and R2 is isopropyl. 
Postupak prema zahtjevu 1, naznačen time, da je komponenta A) spoj sa formulom I, pri čemu R1 je difluorometil, Y je -CHR2-, te R2 je izopropil.
A method of protecting natural substances of plant and/or animal origin, which have been taken from the natural life cycle, and/or their processed forms, which comprises applying to said natural substances of plant and/or animal origin or their processed forms a combination of components A) and B) according to claim 1 in a synergistically effective amount. 
Postupak za zaštitu prirodnih tvari biljnog i/ili životinjskog porijekla koje su preuzete iz prirodnog životnog ciklusa i/ili njihovih obrađenih oblika, od napada gljivica, naznačen time, da sadrži primjenu na navedene prirodne tvari biljnog i/ili životinjskog porijekla ili na njihove obrađene oblike, kombinacije komponenti A) i B) prema zahtjevu 1 u sinergistički učinkovitoj količini.
The composition according to any of the preceding claims, wherein the non-ionic surfactant is selected from Poloxamer 407, Poloxamer 338, Poloxamer 237, Poloxamer 188, and Poloxamer 124. 
Sastav prema zahtjevu 1 ili 2, naznačen time, da je najmanje jedan poloksamerski surfaktant odabran od Poloksamera 188, Poloksamera 407, Poloksamera 237, Poloksamera 338 i Poloksamera 124.
The composition according to any of the preceding claims, wherein the PTH is selected from hPTH(1-84) and a non-human, mammalian PTH molecule, as well as biologically active variants and homologs of hPTH(1-84) and non-human, mammalian PTH molecules. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je PTH odabran od hPTH(1-84) i nehumane, PTH molekule sisavca, kao i biološki aktivne varijante i homologa od hPTH(1-84) i nehumanih, PTH molekula sisavca.
The composition according to any of the preceding claims, wherein said composition further comprises a pharmaceutically acceptable solvent. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da spomenuti sastav nadalje obuhvaća farmaceutski prihvatljivo otapalo.
The composition according to claim 10, wherein the polyol excipient is selected from sorbitol, glycerol, and mannitol. 
Sastav prema zahtjevu 10, naznačen time, da je poliolski ekscipijent odabran od sorbitola, glicerola i manitola.
The composition according to any of the preceding claims, wherein said composition is lyophilized. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je spomenuti sastav liofiliziran.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
and wherein the bifunctional aromatic amine is selected from the group consisting of: Bifuctional aromatic amines: and wherein the oxoamine is selected from the group consisting of: 
i pri čemu bifunkcionalni aromatski amin je odabran iz skupine koja sadrži: Bifunkcionalne aromatske amine: [image] [image] i pri čemu oksoamin je odabran iz skupine koja sadrži:
The reaction mixture of Claim 1, wherein the compound comprising an aromatic ketone moiety is an amino acid or a polypeptide. 
Reakcijska mješavina prema zahtjevu 1, naznačena time da spoj koji sadrži dio aromatskog ketona je amino kiselina ili polipeptid.